Granular Pantoprazole Direct Compression for Acid Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pantoprazole, a proton pump inhibitor, is sensitive to heat and unstable in acidic and moist environments, leading to rapid degradation in gastric fluids, which complicates the formulation of stable pharmaceutical compositions that maintain therapeutic efficacy.
Innovation Solution
Formulating pantoprazole tablets with particles of specific size (60-250 μm) and using a combination of alkalizing substances, fillers, and disintegrants to enable direct compression without water, followed by an enteric coating to protect against acidic conditions, ensuring stability and controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If pantoprazole is formulated using conventional small particle sizes (25 μm), then the drug can be adequately mixed with excipients, but the tablets cannot be directly compressed and require complex granulation processes involving water and prolonged drying
Solution Approach 1:
The patent changes the particle size parameter of pantoprazole from conventional small sizes (25 μm) to a specific range (60-250 μm, preferably 100-250 μm). This parameter change enables the drug to be directly compressed with excipients without requiring complex wet granulation processes, thereby simplifying the manufacturing process while maintaining adequate mixing capability
Solution Approach 2:
The patent extracts and eliminates the need for water-based granulation and prolonged drying steps from the manufacturing process. By using granular pantoprazole particles of optimized size, the formulation can be directly compressed, removing the harmful drying step that exposes heat-sensitive pantoprazole to elevated temperatures for extended periods
2Stability of the object's composition
If pantoprazole is exposed to heat during prolonged drying of granulates, then moisture is removed, but the heat-sensitive drug degrades
Solution Approach 1:
The patent removes the prolonged high-temperature drying step from the manufacturing process by using granular pantoprazole that can be directly compressed. This eliminates the source of heat-induced degradation while still achieving the necessary moisture control through the direct compression process itself
Solution Approach 2:
The patent performs preliminary granulation of pantoprazole into larger particles (60-250 μm) before formulation, which enables direct compression and eliminates the need for subsequent prolonged drying. This preliminary action prevents heat exposure during the formulation process, protecting the heat-sensitive drug from degradation
3Stability of the object's composition
If enteric coating is applied to protect pantoprazole from acid degradation, then drug stability is improved, but the complexity of the formulation increases
Solution Approach 1:
The patent uses an enteric coating as an intermediary protective layer that allows the formulation to withstand acidic gastric conditions. This coating acts as a mediator between the acid-sensitive pantoprazole and the harsh gastric environment, enabling the drug to reach the intestine intact where it can be released and absorbed
Solution Approach 2:
The patent applies enteric coating specifically to the tablet surface, creating a localized protective barrier only where needed (in the acidic stomach environment). The coating provides acid protection where required while allowing rapid disintegration and drug release in the neutral pH environment of the intestine, optimizing protection without unnecessary complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tablets exhibit improved stability and controlled release of pantoprazole, maintaining efficacy by preventing degradation and ensuring rapid disintegration in the intestine, with over 50% of the active ingredient released within 45 minutes and 80% within 60 minutes, even after storage.
Implementation Method 1
pharmaceutical compositions comprising this drug, as well as processes for the manufacture thereof, must be designed to protect the drug from moisture and acidic conditions. Due to the rapid drug degradation that occurs in acidic gastric fluids, such formulations usually comprise an enteric coating.
Implementation Method 2
The most common approach is the use of an alkaline core, a separating layer and an enteric coating. By use of an alkaline substance within the core benzimidazole compounds can be protected against acid degradation.
Data Source
AI summary
Pharmaceutical composition comprising pantoprazole as the active ingredient. The pantoprazole is present in the form of particles having an average particle size within the range of 60 µm to 250 µm. Pantoprazole having an average particle size within the range of 60 µm to 250 µm is prepared by a process comprising the steps of wetting pantoprazole with water having a pH of 10 to 12 in a high shear mixer, passing the wet pantoprazole through a sieve having a mesh size of 0.8 to 2 mm, and drying the mass in a fluid bed dryer .